Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Terns Pharmaceuticals adds former AstraZeneca CMO to board 

By Brian Buntz | September 28, 2021

Terns PharmaceuticalsThe biopharma Terns Pharmaceuticals (NSDQ:TERN) has appointed Dr. ​​Ann E. Taylor to its board of directors. 

Taylor, who served as AstraZeneca‘s chief medical officer from April 2019 to August 2021, has more than 35 years of experience in drug development. Other notable companies she has worked for include Pfizer, Novartis and AstraZeneca subsidiary MedImmune. 

Ann Taylor

Dr. ​​Ann E. Taylor

Dr. Taylor currently serves on the board of directors of Unlearn.AI, a company focused on accelerating clinical trials with artificial intelligence. 

She has authored and co-authored 48 peer-reviewed papers, 27 book chapters and reviews and served on the editorial board of the Journal of Clinical Endocrinology and Metabolism.

Foster City, California–based Terns is focused on developing therapies for nonalcoholic steatohepatitis (NASH), which involves liver inflammation and potentially scarring (cirrhosis). “NASH remains an area of significant unmet need and I believe Terns’ approach, which seeks to combine best-in-class molecules with clinically validated mechanisms in NASH, will play a significant part in the treatment of NASH patients,” said Taylor, in a statement.

Earlier this month, Terns announced it had completed patient enrollment of Part 1 of its AVIATION Trial, a Phase 1b study investigating TERN-201 in NASH. The drug is a highly selective inhibitor of vascular adhesion protein-1 (VAP-1).  


Filed Under: Hepatology
Tagged With: AstraZeneca, Dr. Ann E. Taylor, Terns Pharmaceuticals
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Arrowhead/GSK
GSK could pay Arrowhead $1B to develop NASH RNAi therapeutic 
Ambys Medicines
Ambys Medicines opens cell therapy manufacturing facility, presents data on liver cell data
FibroScan
Noninvasive liver exam plays role in fighting viral hepatitis and fatty liver disease

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50